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Strengths and limitations of this study
 ► The VITDALIZE trial is a large, randomised, double- 
blind, placebo- controlled, international and multi-
centre trial.
 ► The trial will provide important information about 
efficacy of high dose vitamin D administration in 
critically ill patients with severe vitamin D deficiency 
and could be a simple, inexpensive intervention to 
improve patient outcomes and quality of life.
 ► Challenges of the trial include the heterogeneous in-
tensive care unit patient cohort and the high number 
of patients that takes the risk of recruitment failure.
 ► Due to the differing national processes in consent-
ing and monitoring there may be some variance and 
each country will abide by their local ethics commit-
tee consenting procedures.
ABSTRACT
Introduction Observational studies have demonstrated an 
association between vitamin D deficiency and increased 
risk of morbidity and mortality in critically ill patients. 
Cohort studies and pilot trials have suggested promising 
beneficial effects of vitamin D replacement in the critical 
ill, at least in patients with severe vitamin D deficiency. As 
vitamin D is a simple, low- cost and safe intervention, it has 
potential to improve survival in critically ill patients.
Methods and analysis In this randomised, placebo- 
controlled, double- blind, multicentre, international trial, 
2400 adult patients with severe vitamin D deficiency 
(25- hydroxyvitamin D≤12 ng/mL) will be randomised in 
a 1:1 ratio by www. randomizer. at to receive a loading 
dose of 540 000 IU cholecalciferol within 72 hours after 
intensive care unit (ICU) admission, followed by 4000 IU 
daily for 90 days or placebo. Hypercalcaemia may occur 
as a side effect, but is monitored by regular checks of the 
calcium level. The primary outcome is all- cause mortality 
at 28 days after randomisation. Secondary outcomes are: 
ICU, hospital, 90- day and 1- year mortality; hospital and 
ICU length of stay, change in organ dysfunction on day 5 
as measured by Sequential Organ Function Assessment 
(SOFA) score, number of organ failures; hospital and ICU 
readmission until day 90; discharge destination, self- 
reported infections requiring antibiotics until day 90 and 
health- related quality of life. Recruitment status is ongoing.
Ethics and dissemination National ethical approval 
was obtained by the Ethics Committee of the University of 
Graz for Austria, Erasme University Brussels (Belgium) and 
University Hospital Frankfurt (Germany), and will further 
be gained according to individual national processes. On 
completion, results will be published in a peer- reviewed 
scientific journal. The study findings will be presented at 
national and international meetings with abstracts online.
Trial registration NCT03188796, EudraCT- No: 2016-
002460-13.
InTRoduCTIon
Vitamin D has much broader effects on 
various metabolic activities than originally 
expected.1–3 Many recent papers have demon-
strated the pleiotropic effects of vitamin D. 
Vitamin D is a precursor of a steroid hormone 
with a specific nuclear receptor (vitamin D 
receptor), which regulates more than 1000 
genes and is also an important regulator 
of the immune system.4 Besides regulating 
calcium homeostasis, vitamin D has an effect 
on muscles, blood vessels, cell prolifera-
tion and differentiation, and autoimmune 
processes. Therefore, vitamin D deficiency 
causes skeletal and non- skeletal diseases and 
seems to predispose to a variety of respiratory, 
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immune, infectious, neurological and cardiovascular 
diseases.
25- hydroxyvitamin D (25(OH)D) is the major circu-
lating vitamin D metabolite, and its measure best reflects 
an individual’s vitamin D status. Thus, serum 25(OH)
D is the generally accepted parameter for determining 
vitamin D status. Although the definition for vitamin 
D deficiency is still under debate, a cut- off of 25(OH)
D≤12 ng/mL (=30 nmol/L) is uniformly considered 
to represent severe deficiency.5 25(OH)D levels below 
12 ng/mL (or 30 nmol/L) hallmark an increased risk for 
rickets, osteomalacia and decreased fractional calcium 
absorption. Although vitamin D supplementation is inex-
pensive, simple and has an excellent safety profile, testing 
for and treating of vitamin D deficiency is currently not 
routinely performed, particularly in the intensive care 
unit (ICU).
To date, only a few studies have investigated high- dose 
vitamin D in critically ill patients with severe vitamin D 
deficiency.6–8 The largest study to date, the VITdAL- ICU 
randomised, double- blind, placebo- controlled, single- 
centre trial included 492 critically ill patients with vitamin 
D deficiency (25(OH)D≤20 ng/mL) assigned to receive 
either vitamin D or placebo.6 Vitamin D3 or placebo was 
given orally or via nasogastric tube at a dose of 540 000 
IU followed by monthly maintenance doses of 90 000 IU 
for 5 months. The study provided no differences between 
vitamin D and placebo group concerning the primary 
outcome of hospital length of stay, hospital mortality or 
6- month mortality. However, lower hospital mortality was 
observed in the severe vitamin D deficiency subgroup 
(25(OH)D≤12 ng/mL, n=200 or 42% of the total popu-
lation). As this was only a secondary endpoint in the 
predefined subgroup with severe vitamin D deficiency, 
this finding is hypothesis generating and prompted the 
current VITDALIZE study. We hypothesise that vitamin 
D replacement will improve patient’s outcome and 
quality of life in critically ill patients with severe vitamin 
D deficiency.
METhodS And AnAlySIS
Trial design
The VITDALIZE trial is a multicentre, randomised, 
placebo- controlled, double- blind phase III trial targeting 
a sample size of 2400 critically ill patients with severe 
vitamin D deficiency in more than 30 sites in Austria, 
Germany, Belgium, Switzerland and UK.
The aim of the trial is to determine if high- dose vitamin 
D3 improves clinical outcomes and is cost- effective in 
comparison to placebo in adult critically ill patients 
with severe vitamin D deficiency. An extended version 
of the protocol is added as an online supplementary file 
(Protocol_24.01.2018–1.3).
Trial population
The trial population consists of mixed adult critically ill 
patients screened within 72 hours after ICU admission 
anticipated to require ≥48 hours of ICU care at the time 
of screening with documented vitamin D deficiency 
using local routine testing (25(OH)D≤12 ng/mL 
(=30 nmol/L)) recruited in several countries in academic 
and non- academic hospitals. In the UK, where it is not 
possible to test for vitamin D levels in 1 day, samples 
will be processed by an FDA (Food and Drug Adminis-
tration)/CE (Conformité Européenne) approved rapid 
bedside vitamin D3 analyser (Sofia, Quidel, USA) that will 
determine if the patient has severe vitamin D deficiency 
(25(OH)D ≤12ng/mL).
A flowchart of study intervention is seen in figure 1 and 
a schedule of assessment and procedures in table 1.
The day of the study medication loading dose is day 
0 (V1). At day 5 (V2), extensive clinical data will be 
collected. The primary endpoint (28- day mortality) will 
be assessed at V3. A follow- up visit will be done by tele-
phone 90 days after randomisation with patient or family 
physician. This visit will include important safety evalua-
tions and secondary outcomes. A final follow- up visit will 
be done after 1 year.
Recruitment
The single- centre pilot study (VITdAL- ICU) was 
conducted at the Medical University of Graz, a large 
tertiary academic centre with 123 ICU beds. During a 
2- year period, we were able to recruit n=492 critically ill 
adult patients with vitamin D deficiency (<20 ng/mL). 
Severe vitamin D deficiency was found in 42%, or 200 
patients.6 Current data from recruiting sites indicate 
that severe vitamin D deficiency in critically ill patients is 
between 30% and 50%. We will need to recruit an average 
of approximately 2–3 patients per month. Recruitment 
rates are based on previous ICU trials, the VITdAL- ICU 
study and an accepted screen failure rate of 2 out of 3 for 
severe vitamin D deficiency. Given the high prevalence of 
severe vitamin D deficiency and broad eligibility criteria 
we believe this is a conservative but realistic recruitment 
target.
The per- site recruitment will be monitored actively at 
nationally coordinated trial management group meet-
ings. We will aim to identify barriers and solutions to 
help improve the recruitment. Advice from sites with a 
high level of recruitment will be disseminated via tele-
conference. Advice on how to maximise recruitment 
will be sought from our patient partners on a regular 
basis. If centres consistently fail to meet recruitment 
targets, we will recruit additional sites while minimising 
the resources used in maintaining poorly recruiting sites 
or allow higher recruitment rates than planned in high- 
recruiting centres.
Randomisation and blinding
Randomisation and blinding will be performed using the 
secure and validated web- based randomisation service 
‘Randomizer for Clinical Trials’ (Institute for Medical 
Informatics, Statistics and Documentation, Medical 
University of Graz, Austria; available  at: www. randomizer. 
copyright.
 o
n
 D
ecem
ber 16, 2019 at E-Library Insel. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031083 on 12 November 2019. Downloaded from 
3Amrein K, et al. BMJ Open 2019;9:e031083. doi:10.1136/bmjopen-2019-031083
Open access
Figure 1 Trial flow of intervention scheme. We will check eligibility and obtain informed consent* from patients or legally 
authorised representative/healthcare proxy. After evaluation of exclusion criteria, patients will be randomised in the intervention 
or placebo group. Primary endpoint is 28- day all- cause mortality. *When informed consent is not possible at time of screening, 
country- specific alternative strategies for obtaining informed consent are used (ie, in Austria delayed informed consent, in 
Germany, consent of legal representative, England and Wales consent of relatives or responsible clinician). ICU, intensive care 
unit; IU, international unit; MCT, median chain triglycerides; SOFA, Sequential Organ Failure Assessment.
at). Patients will be randomly assigned to either vitamin D 
or placebo in a 1:1 ratio and stratified according to centre 
and gender. To ensure equal group sizes a restricted 
randomisation method will be used.
Allocation concealment will be ensured, as the service 
will not release the randomisation code until the patient 
has been recruited into the trial.
The following method will be used to maintain blinding: 
the blinding list will be kept strictly confidential and no 
routine vitamin D testing is done after study inclusion. 
An independent statistician and unblinded pharmacist 
will keep treatment allocation information confidential 
until database lock. Patient’s group allocation will not 
be revealed until final statistical analysis. In case of safety 
concerns (eg, severe hypercalcaemia >3.5 mmol/L), 
participants of the study may be unblinded by the local 
investigator at each participating site and/or the coordi-
nating centre. This will be done and documented with 
the Randomizer.
Intervention
 ► Vitamin D3 group receiving a bolus of 540 000 I.U. 
vitamin D3, dissolved in medium chain triglycerides 
(MCT, 37.5 mL), at day 0 followed by 4000 IU daily 
(10 drops) for 90 days, or
 ► Placebo group receiving 37.5 mL MCT solution at day 
0 followed by 10 drops MCT for 90 days.
A concomitant routine low dose vitamin D intake of up 
to 800 IU daily is permitted, but very unlikely to have an 
effect in this 90- day time frame and population.
Inclusion and exclusion criteria
Inclusion criteria
 ► Age ≥18 years.
 ► Anticipated ICU stay ≥48 hours.
 ► Admission to ICU ≤72 hours before screening.
 ► Severe vitamin D deficiency (≤12 ng/mL 
(30 nmol/L) or undetectable) using local routine 
testing.
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Table 1 Frequency and scope of study visits
 
Assessment Screening (V0)
Enrolment, 
baseline data (V1)
Clinical data
(V2)
28- day 
mortality (V3)
90- day follow- 
up (V4)
1- year follow- 
up (V5)
Day 0 Day 5 Day 28 Day 90 Month 12
Inclusion/exclusion criteria X X
Informed consent   X
Demographics   X
Randomisation   X
Intervention     
  Loading dose 540 000 
IU
  vitamin D3
  X
  Daily dose 4000 IU 
vitamin D3
    X X X
Outcome variables     
  Mortality     X X X X
  SOFA   X X
  Infections requiring 
antibiotics
    X
  Hospital and ICU 
readmission
    X
  Katz activity of daily life   X X
Safety evaluation     
  Serum calcium X X X
  Falls/fractures     X
  New episodes of 
nephrolithiasis
    X
  Creatinine     X
ICU, intensive care unit; SOFA, Sequential Organ Function Assessment.
Exclusion criteria
 ► Severe gastrointestinal dysfunction/unable to receive 
study medication.
 ► Patients with a do not resuscitate order/imminent 
death.
 ► Not expected to survive initial 48 hours of admission 
or treatment withdrawal imminent within 24 hours.
 ► Hypercalcaemia (>2.65 mmol/L total calcium and/or 
>1.35 mmol/L ionised calcium at screening).
 ► Known kidney stones, active tuberculosis or sarcoidosis 
(within the last 12 months).
 ► Pregnancy/lactation.
 ► Hypersensitivity to drug or excipient.
outcome measures
The primary outcome of this trial will be all- cause 
mortality at day 28 after randomisation.
Secondary outcomes include 90- day and 1- year all- 
cause mortality, ICU and hospital mortality and length of 
stay, change in organ dysfunction on day 5 as measured by 
the SOFA score (Sequential Organ Function Assessment) 
and the number of organ failures (0–6; as defined by 
>2 SOFA points in each of the six categories). The six cate-
gories comprise the respiratory system (PaO2/FiO2), the 
nervous system (Glasgow coma scale), the cardiovascular 
system (mean arterial pressure OR administration of 
vasopressors required), the liver (bilirubin), the coagula-
tion (number of platelets) and the kidney (creatinine or 
urine output).
Further secondary endpoints are hospital and ICU read-
mission rate until day 90, discharge destination (home, 
rehabilitation, other hospital), self- reported infections 
requiring antibiotics until day 90 and the Katz activities of 
daily life, the most appropriate instrument to assess func-
tional status as a measurement of the patient’s ability to 
perform basic activities independently, at day 90 will be 
collected using a questionnaire.
Mortality at day 28, day 90 and 1 year will be enquired 
by telephone, through hospital information system 
and national data linkage systems (where available). 
SOFA scores will be generated by collection of routinely 
collected clinical data.
Safety outcomes comprise hypercalcaemia at day 5, self- 
reported or documented falls and fractures until day 90 
and new episodes of kidney stones.
In the UK arm, a near patient testing device for rapid 
vitamin d assessment will be used. Additional secondary 
outcomes are Health- related quality of life (EQ- 5D- 5L, 
a standardised instrument for measuring generic health 
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status) and a disability assessment (WHO- DAS 2.0 (WHO 
Disability Assessment Schedule 2.0), a generic assessment 
instrument for health and ability) at 90 days and 1 year. 
EQ- 5D- 5L and WHODAS 2.0 EQ- 5D are designed for self- 
completion and as such captures information directly 
from the respondent. Further additional secondary 
endpoints in the UK arm are secondary healthcare util-
isation in the first year (ICU and hospital length of stay, 
readmissions and utilisation of hospital and community 
care resources after hospital discharge 1 year after rando-
misation), from Hospital Episode Statistics, civil registry 
data held by NHS Digital and patient questionnaires and 
health economics analysis including cost effectiveness of 
screening for and treating vitamin D deficiency in critical 
illness and cost per quality- adjusted life year gained 1 year 
after randomisation and at end of life.
Monitoring
Patients will be monitored daily until ICU discharge and 
serious adverse events will be reported to the regulatory 
authorities, other participating centres and the manufac-
turer of the study medication. Following site- initiation the 
need for further site monitoring visits will be assessed on 
an individual and risk proportionate approach. Further 
site monitoring visits may be triggered by the following: 
poor quality data returns, repeated issues with randomis-
ation (ineligible patients being entered), repeated issues 
with consenting, non- compliance with the protocol or 
good clinical practice, unusual data patterns or safety 
reporting issues. This may vary depending on national 
oversight processes.
The DSMB (data safety monitoring board) is respon-
sible for safeguarding the interests of trial subjects, 
assessing the safety and efficacy of the interventions 
during the trial, and for monitoring the overall conduct 
of the clinical trial. The DSMB will assess the progress of 
the trial at regular intervals (~6 months) and will evaluate 
all safety data. In addition, the DSMB will evaluate the 
results of the interim efficacy analysis. It will recommend 
to the coordinating investigator and the sponsor whether 
to continue or stop the trial.
Sample size considerations
The sample size for this multinational study is based on the 
primary endpoint 28- day mortality. In the VITdAL- ICU 
study, 28- day mortality rates of 36% (37/102) in the 
placebo group and 20% (20/98) in the vitamin D Group 
were observed.6 The VITDALIZE study has been designed 
to be sufficiently powered to detect a smaller, but clini-
cally relevant absolute mortality difference of 5% with a 
power of 80% with an assumed baseline mortality rate of 
25%. This corresponds to a clinically highly relevant rela-
tive risk reduction of 20%.
Multicentre trials generally have a smaller treatment 
effect than monocentre studies.9 We assume that this will 
also be the case for the VITDALIZE study. Furthermore, 
our assumed 5% absolute mortality difference is in line 
with a recent survey among clinical intensivists that the 
largest median treatment effect considered plausible by 
intensivists for current ongoing ICU multicentre trials is 
3%–5%.10
Using a fixed sample size design and a two- sided log- 
rank test for equality of survival curves with a two- sided 
alpha level of 5%, a sample size of n=1093 per group will 
be needed to achieve a power of 80% (total sample size 
of 2186).
Incorporating one interim analysis after inclusion of 
50% of the patients a total sample size of at least n=2194 
(494 events) is required to achieve 80% power using an 
O’Brien- Fleming spending function.11 Accounting for a 
drop- out rate of approximately 10% yields a total sample 
size of n=2400 patients. For sample size calculation the 
software package nQuery 7.0+nTerim 2.0 was used.
Statistical analysis
The primary analysis will be performed on the intention- 
to- treat population (ITT). The ITT will include all 
patients who receive at least the loading dose of the study 
medication. All patients will be analysed according to the 
treatment assignment during randomisation. The per 
protocol population will include all patients who received 
the loading dose and have a compliance >80%. Compli-
ance is defined as self- reported percentage of doses 
ingested until day 90.
The safety analyses will be based on the treated set, 
which is defined as all randomised patients who receive 
at least one dose of trial medication. All patients will be 
analysed according to the treatment they received.
Data analysis
All clinical and safety data collected in the study will 
be analysed with SAS V.9.4. Data will be presented as 
summary tables and, where appropriate, as plots. Contin-
uous data will be described by means, standard deviation, 
medians and upper and lower quartiles unless otherwise 
stated. The number of observations and minimum and 
maximum values are also included.
Categorical data will be summarised using frequencies 
and percentages.
The primary outcome, 28- day all- cause mortality, will be 
displayed using Kaplan- Meier estimates of survival curves 
in each treatment arm. Group comparison will be made 
using a stratified two- sided log rank test. The unstratified 
log- rank test will be performed as a sensitivity analysis. 
The Cox regression model, including treatment and strat-
ification factor, will be used to estimate the hazard ration 
and its 95% confidence interval. Details will be defined in 
a Statistical Analysis Plan.
ICU, hospital mortality, 90- day mortality and 1- year 
mortality will be analysed as secondary outcomes using 
Kaplan- Meier estimates of survival curves. For the other 
secondary parameters, comparison between groups will 
be performed using appropriate parametric or non- 
parametric methods and χ2 tests.
The safety outcomes, (hypercalcaemia on day 5, new 
kidney stones, self- reported falls and fractures until day 
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90) will be analysed as binary variables and compared 
with χ2 tests.
Demographic and baseline characteristics
In a summary of demographic, baseline and diagnostic 
characteristics (age, weight, height, sex, SAPS III, 
Charlson comorbidity index) a comparison of the treat-
ment groups will be performed. To this end, appropriate 
descriptive and inferential statistics will be applied. Rele-
vant medical history will be also displayed using summary 
statistics according to the two treatment groups.
Subgroup analysis
Predefined subgroup analyses will be performed for all 
primary and secondary outcomes based on the following 
group definitions as exploratory analysis:
Kidney function (CKD 4 or lower vs higher at inclusion).
Sepsis (admission diagnosis) versus non- sepsis defined 
by the 2016 criteria (suspected infection/qSOFA on day 
0—respiratory rate of 22/min or greater, altered menta-
tion, or systolic blood pressure of 100 mm Hg or less).
Missing data handling
All available data will be used in the analyses and data 
summaries. There will be no imputation of any missing 
data.
Planned interim analysis
The trial uses a group sequential design with one interim 
analysis when 50% of the planned enrolled patients in 
each arm (n=600 per arm) have completed their day 28 
assessment by the independent data safety monitoring 
board. The enrolment of patients will continue while 
the interim analysis is performed. This interim analysis 
is intended to test for efficacy, that is, the trial may be 
terminated after the interim analysis, if the main question 
can already be answered at this interim analysis. If the 
interim analysis shows a benefit for the vitamin D group, 
the DSMB may recommend early study termination. The 
interim analysis will be performed only for the primary 
outcome 28- day mortality. The O’ Brien- Fleming rule will 
be used to stop the trial early for efficacy. In detail, if the 
p value of the log rank test is smaller than 0.003, then the 
trial can be stopped early by the DSMB.
dISCuSSIon
Recent studies have demonstrated that low vitamin D levels 
are an independent risk factor for mortality in critically ill 
patients12–17 reflecting the relevant role of vitamin D.
Worldwide, the prevalence of vitamin D deficiency in 
intensive care patients ranges between 40% and 70%. 
Therapeutic interventions like surgery, fluid resuscita-
tion, extracorporeal membrane oxygenation, cardio-
pulmonary bypass, dialysis and plasma exchange and 
hepatic, parathyroid and renal dysfunction may signifi-
cantly reduce vitamin D levels.18
Pleiotropic effects of vitamin D on the immune system, 
glucose metabolism, and calcium homeostasis are 
essential in critically ill patients. Vitamin D deficiency 
carries an additional risk due to mortality and morbidity 
to these patients. ICU patients often suffer from immu-
nological dysfunction and changes in body composition 
(loss of muscle mass, increase in the adipose tissue). 
Every additional day staying on ICU increases the chance 
of becoming dependent on care with prolonged rehabili-
tation and recovery time. Interventions, such as vitamin D 
supplementation, may also have the potential to improve 
health related quality of life.
A recent Cochrane meta- analysis19 with 50 623 adults 
who were healthy or were recruited among the general 
population, or diagnosed with a specific disease, showed 
that vitamin D3 supplementation was linked to signifi-
cantly improved survival. An individual patient data 
analysis from eight major vitamin D trials with >70 000 
participants showed a reduction of mortality by vitamin 
D by 9%.20 Genetically low 25(OH)D is associated with 
increased all- cause mortality.21 An observational cohort 
study of 4344 adults hospitalised between 1993 and 2011 
demonstrated that in those patients with prehospital 
25(OH)D concentrations <20 ng/mL, an improvement 
in vitamin D status during the year leading up to hospi-
talisation was independently associated with improved all- 
cause mortality and decreased hospital length of stay.22
Recently, in a double- blind, randomised controlled 
study, it was demonstrated that the administration of high 
dose vitamin D (up to 500 000 IU) increased levels of anti- 
microbial molecules23 that may have beneficial effects on 
critical illness and inflammatory outcomes.
Although vitamin D supplementation is inexpensive, 
simple and has an excellent safety profile, testing for and 
treating of vitamin D deficiency is currently not routinely 
performed in ICU patients.
The VITDALIZE trial is a large randomised, multi-
centre international study designed to demonstrate the 
clinical benefit of vitamin D supplementation in critically 
ill patients with severe vitamin D deficiency. The primary 
outcome will be 28- day all- cause mortality. All- cause 
mortality represents a ‘hard’ endpoint that is not prone 
to measurements bias. Most importantly, the European 
Medicines Agency recently recommended short- term 
(28 day) all- cause mortality as the most relevant primary 
efficacy endpoint in confirmatory clinical trials assessing 
the efficacy of drugs or medicinal products in patients 
with life- threatening acute illnesses, for example, in crit-
ically ill patients with sepsis24 or with acute respiratory 
distress syndrome.25 Long- term effects will be reflected by 
the secondary endpoints 90 days and 1- year mortality and 
the secondary endpoint Katz Activity of Life will reflect 
the health related quality of life. The UK arm will also 
be assessing the cost- effectiveness and health economics 
with further health- related quality measures of the 
intervention.
Due to the differing national processes in consenting 
and monitoring there may be some variance and each 
country will abide by their local ethics committee 
consenting procedures.
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The VIOLET (Vitamin D to improve outcomes by 
leveraging early treatment;  ClinicalTrials. gov Identifier: 
NCT03096314) trial is another important and similar, yet 
substantially different RCT that has stopped recruitment 
in July 2018 but no results have been published at the 
time of writing. VIOLET included patients with vitamin 
D deficiency (point- of- care test, <20 ng/mL), but not 
necessarily ICU patients. The intervention consisted of a 
single bolus loading dose (540 000 IU vitamin D3), but 
no maintenance dose; and the primary endpoint is 90- day 
mortality. Together, these two large trials in acutely ill 
patients will greatly advance our knowledge in this field.
As vitamin D3 application is a simple, low- cost, safe 
and well- tolerated intervention, it has great potential to 
improve survival and quality of life in critically ill patients 
and could be implemented worldwide immediately.
EThICS And dISSEMInATIon
Study protocol (V.1.3, EudraCT- No. 2016-002460-
13), patient information, and informed consent were 
approved by the leading Ethics Committee of the Univer-
sity of Graz (EK 1289/2016), and will be submitted to 
each participating trial centre. In the meanwhile, study 
protocol has been approved by the leading national 
Ethics Committee of the Erasme University Brussels for 
Belgium and University Hospital Frankfurt for Germany.
Informed consent to participate in the study will be 
gained by patients, relatives, physicians, and/or legal 
represenatives, depending on national regulatory 
specifications.
Recruitment in Austria started in October 2017 and 
in Belgium in January 2019. The current study protocol 
(V.1.3) was released in January 2018. This trial was regis-
tered at http:// clinicaltrials. gov in June 2017. So far, more 
than 390 patients have been randomised in >15 active 
centres. The planned recruitment lasts for approximately 
another 36 months. The UK is funded by NIHR HTA and 
projected to start recruitment in 2020. Germany will be 
funded by the BMBF (Federal Ministry of Education and 
Research) and will start recruitment in 2020. In addition, 
ESICM and Fresenius Kabi support funding. The partic-
ipation of Switzerland is planned, but will depend on 
funding possibilities.
On completion, results will be published in a peer- 
reviewed scientific journal.
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